Thus, to evaluate the potential therapeutic implications of COX-2 upregulation by dying cancer cells for tumor immunity, we determined the impact of pharmacologically inhibiting COX-2 alongside ICB and CTX. This evidence concerns the gene PTGS2 and neoplasm.